Effects of estrogen and raloxifene on synaptic density in the hippocampal CA1 region of ovariectomized rats

Imagem de Miniatura
Arquivos
art_MENEZESDASILVA_Effects_of_estrogen_and_raloxifene_on_synaptic_density_2023.PDF (974.73 KB)
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER ESPANA
Autores
MENEZESDASILVA, Glaucia Mara
VEIGA, Eduardo Carvalho de Arruda
Citação
CLINICS, v.78, article ID 100312, 6p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Introduction: The CA1 region of the hippocampus has an important role in learning and memory. It has been shown that estrogen deficiency may reduce the synaptic density in the region and that hormone replacement ther-apy may attenuate the reduction. Objectives: This study aimed to evaluate the effects of estrogen and raloxifene on the synaptic density profile in the CA1 region of the hippocampus in ovariectomized rats.Methods: Sixty ovariectomized three-month-old virgin rats were randomized into six groups (n = 10). Treatments started either three days (early treatment) or sixty days (late treatment) after ovariectomy. The groups received propylene glycol vehicle (0.5 mL/animal/day), equine conjugated estrogens (50 mu g/animal/day), or raloxifene (3 mg/kg/day) either early or late after ovariectomy. The drugs were administered orally by gavage for 30 days. At the end of the treatments, the animals were anesthetized and transcardially perfused with ether and saline solu-tion. The brains were removed and prepared for analysis under transmission electron microscopy and later fixed. Results: Results showed a significant increase in the synaptic density profile of the hippocampal CA1 region in both the early estrogen (0.534 +/- 0.026 mu/m2) and the early raloxifene (0.437 +/- 0.012 mu/m2) treatment groups compared to the early or late vehicle-treated control groups (0.338 +/- 0.038 mu/m2 and 0.277 +/- 0.015 mu/m2 respectively).Conclusions: The present data suggest that the raloxifene effect may be lower than that of estrogen, even early or late treatment, on synaptic density in the hippocampus.
Palavras-chave
Estrogen, Hormone therapy, Raloxifene, Hippocampus, CA1 region, Ovariectomy
URI
https://observatorio.fm.usp.br/handle/OPI/57982
Referências
  1. Ahmad S, 2017, PHARM BIOL, V55, P1295, DOI 10.1080/13880209.2017.1299768
  2. Andrade PM, 2002, GYNECOL ENDOCRINOL, V16, P265, DOI 10.1080/713603094
  3. Arevalo MA, 2015, NAT REV NEUROSCI, V16, P17, DOI 10.1038/nrn3856
  4. BENSON P F, 1961, Cereb Palsy Bull, V3, P510
  5. Brand BA, 2023, SCHIZOPHRENIA BULL, DOI 10.1093/schbul/sbad058
  6. Brandt N, 2013, INT J DEV BIOL, V57, P351, DOI 10.1387/ijdb.120217gr
  7. Brasil FB, 2009, ANAT REC, V292, P587, DOI 10.1002/ar.20878
  8. Brizand V, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00022
  9. Condi FLF, 2012, CLIMACTERIC, V15, P441, DOI 10.3109/13697137.2011.624213
  10. Corvino V, 2015, FRONT CELL NEUROSCI, V9, DOI [10.3339/fncel.2015.00433, 10.3389/fncel.2015.00433]
  11. Dye Richelin V, 2012, Int J Alzheimers Dis, V2012, P258454, DOI 10.1155/2012/258454
  12. Carbonel AAF, 2011, MENOPAUSE, V18, P93, DOI 10.1097/gme.0b013e3181e5ee25
  13. Frick KM, 2015, LEARN MEMORY, V22, P472, DOI 10.1101/lm.037267.114
  14. Gibbs RB, 2009, HORM BEHAV, V56, P73, DOI 10.1016/j.yhbeh.2009.03.003
  15. Grassi D, 2015, ENDOCRINOLOGY, V156, P3706, DOI 10.1210/en.2014-2010
  16. Gurvich C, 2019, PSYCHONEUROENDOCRINO, V100, P113, DOI 10.1016/j.psyneuen.2018.10.001
  17. Hara Y, 2015, PHYSIOL REV, V95, P785, DOI 10.1152/physrev.00036.2014
  18. Hogervorst E, 2000, NEUROSCIENCE, V101, P485, DOI 10.1016/S0306-4522(00)00410-3
  19. Huerta-Ramos E, 2014, EUR NEUROPSYCHOPHARM, V24, P223, DOI 10.1016/j.euroneuro.2013.11.012
  20. Jacques Amanda C, 2013, Can J Hosp Pharm, V66, P347
  21. Jisa E, 2001, BIOCHEM PHARMACOL, V62, P953, DOI 10.1016/S0006-2952(01)00731-6
  22. Khan MM, 2015, J STEROID BIOCHEM, V146, P38, DOI 10.1016/j.jsbmb.2014.05.001
  23. Littleton-Kearney MT, 2002, CNS DRUG REV, V8, P309
  24. Martinkovich S, 2014, CLIN INTERV AGING, V9, P1437, DOI 10.2147/CIA.S66690
  25. Maximov PY, 2013, CURR CLIN PHARMACOL, V8, P135, DOI 10.2174/1574884711308020006
  26. Moen MD, 2008, DRUGS, V68, P2059, DOI 10.2165/00003495-200868140-00008
  27. Morishima S, 2008, MED MOL MORPHOL, V41, P132, DOI 10.1007/s00795-008-0403-1
  28. Mukherjee J, 2017, P NATL ACAD SCI USA, V114, P11763, DOI 10.1073/pnas.1705075114
  29. Newhouse P, 2015, HORM BEHAV, V74, P173, DOI 10.1016/j.yhbeh.2015.06.022
  30. Olga NK, 2006, BEHAV BRAIN RES, V170, P233, DOI 10.1016/j.bbr.2006.02.026
  31. Picollo C, 2012, ARQ BRAS MED VET ZOO, V64, P860, DOI 10.1590/S0102-09352012000400011
  32. Sherwin BB, 1996, OBSTET GYNECOL, V87, pS20, DOI 10.1016/0029-7844(95)00431-9
  33. Silva I, 2003, MENOPAUSE, V10, P406, DOI 10.1097/01.GME.0000064816.74043.E9
  34. Spencer-Segal JL, 2012, NEUROSCIENCE, V202, P131, DOI 10.1016/j.neuroscience.2011.11.035
  35. Waters EM, 2009, BRAIN RES, V1290, P1, DOI 10.1016/j.brainres.2009.06.090
  36. Weickert TW, 2017, FRONT PSYCHIATRY, V8, DOI 10.3389/fpsyt.2017.00202
  37. Wellington D, 2013, J AM ASSOC LAB ANIM, V52, P481
  38. Yan Y, 2017, ONCOTARGET, V8, P21892, DOI 10.18632/oncotarget.15702
  39. Zárate S, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00430
  40. Zhao YG, 2017, J STEROID BIOCHEM, V174, P96, DOI 10.1016/j.jsbmb.2017.08.003

Coleções
Artigos e Materiais de Revistas Científicas - FM/MOG
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HU
Artigos e Materiais de Revistas Científicas - LIM/58